Navigation Links
NutraCea Announces First Quarter 2008 Financial Results
Date:5/12/2008

ferred revenue 291,000 90,000

Note payable, current portion 4,424,000 23,00

Total current liabilities 18,361,000 7,619,000

Long-term liabilities:

Long-term liabilities 6,278,000 -

Notes payable, net of current portion 71,000 77,000

Total liabilities 24,710,000 7,696,000

Commitments and contingencies

Shareholders' equity:

Common stock, no par value,

350,000,000 shares authorized,

145,525,000 and 144,108,000 shares

issued and outstanding 179,237,000 177,813,000

Accumulated deficit (67,968,000) (61,216,000)

Foreign currency cumulative

translation gain 111,000 -

Total shareholders' equity 111,380,000 116,597,000

Total liabilities and shareholders'

equity $136,090,000 $124,293,000

NUTRACEA AND SUBSIDIARIES

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

Quarters ended

March 31, 2008 March 31, 2007

Revenues

Net product sales $5,084,000 $1,987,000

Royalty 27,000 10,000

Total revenue 5,111,000 1,997,000

Cost of goods sold 4,279,000 1,113,000

Product warranty cost 515,000 -

Total cost of sales 4,794,000 1,113,000

Gross Margin
'/>"/>

SOURCE NutraCea
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. NutraCea Appoints Financial Relations Board as New Investor Relations Firm
2. NutraCea to Host Third Quarter 2007 Financial Results Conference Call November 14
3. NutraCea Announces Conference Call to Report Second Quarter Financial Results
4. NutraCea Forms Joint Ventures With HerbalScience to Develop Nutraceutical Extracts and Pharmaceutical Chemistries From Stabilized Rice Bran
5. NutraCea Provides Update on Domestic Operations
6. NutraCea Files Universal Shelf Registration Statement
7. NutraCea to Purchase Largest Rice Bran Oil Processing Facility in South America
8. New World Record Holder in Powerlifting Credits NutraCeas Unique Rice-Bran-derived Product as his Secret Weapon
9. NutraCea Appoints New Chief Financial Officer
10. NutraCea-Sponsored Study Demonstrates Benefits of Replacing Wheat Flour with Stabilized Rice Bran (SRB) in Battered and Fried Product Applications
11. Demand for NutraCea Rice Bran Oil Prompts Major Expansion of Irgovel Plant Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...srupt normal development, mouse study finds , ... few glasses of wine over a short period in early ...chers from the Medical College of Georgia. , T...affects one in 1,000 babies, include facial malfor...ye openings, and a short nose. Researchers are inv...
(Date:8/29/2008)...-FirstCall/ -- Landauer, Inc. (NYSE:,LDR) announce...ular,quarterly cash dividend of $0.50 per share fo...will be paid on October 3, 2008, to shareholders o... Landauer is the leading provider of analytical se... radiation exposure. For more than 50 years,the C...
(Date:8/29/2008)...Telemedicine Encounter Management Systems (TEMS) t... possible solution to national health care problem...WEB) August 29, 2008 -- If there has been any one ...Democratic National Convention it has been the par...lth care issues., , ,Our Democratic leadership rec...
(Date:8/28/2008)...ia led to daytime tiredness, symptoms of depressio... -- Older adults who live with and provide direct ...ve significantly worse sleep than other older adul... 31 caregivers and 102 noncaregivers, ages 60 to 8...t than non-caregivers and took about 10 minutes lo...
Breaking Medicine News(10 mins):Health News:Alcohol in Early Pregnancy May Prompt Fetal Cell Death 2Health News:AMD Global Telemedicine Inc. Invited to Attend Democratic National Convention 2Health News:Older Caregivers Prone to Worse Sleep Patterns 2
...he University of Pennsylvania’s School of Medicine...gene that it is possible //to inhibit bone decay w...is concept may lead to drug treatments for osteopo...won Choi, PhD, professor of Pathology and Laborato...
...ommon form of brewer's yeast, University of Wiscon...ions of a key protein// that allow it to act as a ...nes gene activity and that, when malfunctioning in...rological disorders. The work, published in the De...
...o drug delivery has been achieved. This is made po...stable glass made from organic material.// It can...l Science has reported the advanced processing by ...son and the National Institute of Standards and Te...
...ursor has been found to be effective to reduce tum...vels of human epidermal growth factor receptor (HE...igh levels of HER2.This is presumed to be the feat...to many treatments including chemotherapy drugs. ...
Other Medicine News:Health News:Targeting a Single Gene Could Inhibit Bone Decay and Stimulate Bone Growth 2Health News:From a Lowly Yeast, Researchers Divine a Clue to Human Disease 2Health News:Drugs Delivery Revolutionized by Extremely Stable Glass 2Health News:Vitamin E Precursor Alpha-TOS Found Effective Against Breast Cancer Cells 2
(Date:8/27/2008)...2 trial, expected by mid-2009 - - Data from secon..., ROCKVILLE, Md., Aug. 27 /PRNewswire-FirstCall/ ...day announced it has completed enrollment,and init...Phase 3,randomized clinical trials of LymphoStat-B...upus erythematosus (SLE). Belimumab is being devel...
(Date:8/26/2008)... safely six weeks following surgical,treatment, R...Six weeks following,bunion surgery, most patients,...back behind the wheel of a car again. A study publ...one and Joint Surgery ( http://www.jbjs.org/ ),als...ents who underwent a,first metatarsal osteotomy (a...
(Date:8/26/2008)...eros Corporation today announced the,publication o...gating,OMS103HP in arthroscopic anterior cruciate ... an investigational drug product that is added to,...o improve postoperative,knee function and motion, ...rlier return to work. The article titled "Novel Dr...
(Date:8/25/2008)...ire/ -- Anthera Pharmaceuticals,Inc., a privately ...lammatory drugs, today announced the initiation of...s with Near-term Cardiovascular,Inflammation Suppr...act of,varespladib when administered to patients w... event., The FRANCIS trial is designed to assess ...
Breaking Medicine Technology:Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Braking After Bunion Surgery 2Braking After Bunion Surgery 3Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery 2Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial 2Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial 3Capsule endoscopy turning up undiagnosed cases of Crohns disease 3774 1Capsule endoscopy turning up undiagnosed cases of Crohns disease 3774 2UD named a regional research participant in National Children 26 23146 3Bs Study 819 1UD named a regional research participant in National Children 26 23146 3Bs Study 819 2MIT 3A blood may help us think 816 1MIT 3A blood may help us think 816 2Chloroplast f and m Thioredoxins Discovered in Nonphotosynthetic Tissues 815 1Chloroplast f and m Thioredoxins Discovered in Nonphotosynthetic Tissues 815 2Chloroplast f and m Thioredoxins Discovered in Nonphotosynthetic Tissues 815 3
...t Finds Taxus Stent,Implantation of Multiple Sten...ors of Need for Another Procedure, , MIAMI LAKES...etwork/ -- An analysis of data from the Western De...ved the CYPHER(R),Sirolimus-eluting Coronary Stent... another procedure at that same lesion site (a,cli...
...2002 , CHICAGO/DARMSTADT, Germany, June 4, 2007 &n...ay at the American Society of,Clinical Oncology (A...nical activity of cilengitide in patients with new...ggressive form of brain tumor.,Cilengitide is a hi...mor and its vasculature. , Fifty-two patients with...
Other Medicine Technology:New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World Clinical Settings 2New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World Clinical Settings 3Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 2Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 3Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 4Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 5
Streck-Detergent III is a balanced electrolyte solution for use as a rinsing and hemoglobin blanking diluent. It is manufactured for the Abbott CELL-DYN® 1400, 1600, 3500 and 3700. The shelf life
An environmentally-safe, CN-free lytic reagent designed for use on the Abbott CELL-DYN® 1800 three-part differential hematology analyzer.
...us Retics is a 5-part differential control that co...r the Abbott CELL-DYN 3200, 3500, 3700 and 4000 in...ated red blood cells that can be analyzed and enum...tomated and manual reticulocyte values for all thr...
Para 12 Plus is a hematology control for the Abbott CELL-DYN 3000, 3200, and 3500/3700. Assay values are provided for the five-part white cell differential, as well as a three-part differential on th
Medicine Products: